At the 57th annual meeting of the American Society of Hematology (ASH), Penn Medicine researchers presented research of 57 patients with chronic lymphocytic leukemia (CLL) who underwent analysis of tumor DNA using next-generation sequencing in order to identify potentially targetable pathways for intervention. Testing at the Penn Medicine Center for Personalized Diagnostics (CPD) uncovered 12 mutations that may be targetable using therapies already available for other cancers.
Read the Department of Communications news release.
Link to ASH abstract.